Drugs / P-CTL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02895412 | Aug 2016 → Dec 2020 | acute myeloid leukemia | University of Sydney | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P-CTL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02895412 ↗ |
| Modality | Cell therapy | “cytotoxic T lymphocytes specific for multiple opportunistic pathogens” NCT02895412 ↗ |
| Route | Other | “One infusion of 2 x 107/m2 P-CTLs prophylactically” NCT02895412 ↗ |